Ms. Celia Economides reports

AURINIA PHARMACEUTICALS TO RELEASE FIRST QUARTER 2018 FINANCIAL RESULTS ON MAY 10, 2018

Aurinia Pharmaceuticals Inc. will release its first quarter 2018 financial results on May 10, 2018, after the market closes. Aurinia's management will host a conference call to discuss the company's first quarter 2018 financial results and provide a general business update.

The conference call and webcast are scheduled for May 10, 2018, at 4:30 p.m. EDT. To participate in the conference call, please dial 1-877-407-9170 (toll-free United States and Canada). An audio webcast can be accessed under news/events through the investors section of the Aurinia corporate website. A replay of the webcast will be available on Aurinia's website.

About Aurinia Pharmaceuticals Inc.

Aurinia is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of LN, FSGS and DES. The company is headquartered in Victoria, B.C., and focuses its development efforts globally.

We seek Safe Harbor.